Roslyn Wallace

560 total citations
15 papers, 224 citations indexed

About

Roslyn Wallace is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Roslyn Wallace has authored 15 papers receiving a total of 224 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 8 papers in Radiology, Nuclear Medicine and Imaging and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Roslyn Wallace's work include Cancer Immunotherapy and Biomarkers (10 papers), Prostate Cancer Treatment and Research (5 papers) and Radiomics and Machine Learning in Medical Imaging (4 papers). Roslyn Wallace is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Prostate Cancer Treatment and Research (5 papers) and Radiomics and Machine Learning in Medical Imaging (4 papers). Roslyn Wallace collaborates with scholars based in Australia, United States and France. Roslyn Wallace's co-authors include Shahneen Sandhu, Rodney J. Hicks, Michael S. Hofman, Joanne Edwards, Arfon Powell, Ruth F. McKee, John H. Anderson, Paul G. Horgan, James J. Going and Amir Iravani and has published in prestigious journals such as Journal of Clinical Oncology, Radiology and Annals of Oncology.

In The Last Decade

Roslyn Wallace

15 papers receiving 220 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Roslyn Wallace Australia	7	149	99	98	27	26	15	224
Eric Thunnissen Netherlands	5	129 0.9×	56 0.6×	122 1.2×	26 1.0×	62 2.4×	6	223
Hina Shah United States	9	91 0.6×	58 0.6×	85 0.9×	15 0.6×	7 0.3×	22	197
Manuela Racca Italy	11	132 0.9×	187 1.9×	156 1.6×	22 0.8×	46 1.8×	27	304
Francesco Mattana Italy	7	62 0.4×	91 0.9×	147 1.5×	24 0.9×	32 1.2×	20	228
Ray Manneh Kopp Spain	9	69 0.5×	33 0.3×	83 0.8×	38 1.4×	44 1.7×	35	172
Elisa Tardelli Italy	10	88 0.6×	132 1.3×	109 1.1×	15 0.6×	76 2.9×	15	297
Weijun Ding China	9	66 0.4×	92 0.9×	152 1.6×	48 1.8×	61 2.3×	15	365
Delphine Daydé France	4	148 1.0×	30 0.3×	44 0.4×	68 2.5×	29 1.1×	10	223
Cristiane Gomes-Lima United States	10	66 0.4×	28 0.3×	51 0.5×	44 1.6×	20 0.8×	16	244
Frédérique Penault-Llorca France	3	270 1.8×	36 0.4×	161 1.6×	29 1.1×	82 3.2×	4	313

Countries citing papers authored by Roslyn Wallace

Since Specialization

Citations

This map shows the geographic impact of Roslyn Wallace's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roslyn Wallace with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roslyn Wallace more than expected).

Fields of papers citing papers by Roslyn Wallace

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roslyn Wallace. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roslyn Wallace. The network helps show where Roslyn Wallace may publish in the future.

Co-authorship network of co-authors of Roslyn Wallace

This figure shows the co-authorship network connecting the top 25 collaborators of Roslyn Wallace. A scholar is included among the top collaborators of Roslyn Wallace based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roslyn Wallace. Roslyn Wallace is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Iravani, Amir, Roslyn Wallace, Serigne Lo, et al.. (2023). FDG PET/CT Prognostic Markers in Patients with Advanced Melanoma Treated with Ipilimumab and Nivolumab. Radiology. 307(3). e221180–e221180. 11 indexed citations

Wallace, Roslyn, Balasubramanian Krishnamurthy, Thomas W. H. Kay, et al.. (2023). Increased Thyroidal Activity on Routine FDG-PET/CT after Combination Immune Checkpoint Inhibition: Temporal Associations with Clinical and Biochemical Thyroiditis. Cancers. 15(24). 5803–5803. 7 indexed citations

Iravani, Amir, Arian Lasocki, Roslyn Wallace, et al.. (2023). Imaging for assessment of cancer treatment response to immune checkpoint inhibitors can be complementary in identifying hypophysitis. Frontiers in Endocrinology. 14. 1295865–1295865. 4 indexed citations

Lau, Peter K. H., S.J. Harris, Melissa Eastgate, et al.. (2023). CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma.. Journal of Clinical Oncology. 41(16_suppl). 9525–9525. 1 indexed citations

Sandhu, Shahneen, Anthony M. Joshua, Louise Emmett, et al.. (2023). LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 41(16_suppl). 5005–5005. 43 indexed citations

Kostos, Louise, James P Buteau, Shahneen Sandhu, et al.. (2023). Efficacy of systemic therapy following [¹⁷⁷Lu] Lu-PSMA in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 41(6_suppl). 77–77. 4 indexed citations

Sandhu, Shahneen, Anthony M. Joshua, Louise Emmett, et al.. (2022). PRINCE: Phase I trial of ¹⁷⁷Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 40(16_suppl). 5017–5017. 34 indexed citations

Sandhu, Shahneen, Anthony M. Joshua, Louise Emmett, et al.. (2021). 577O PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC). Annals of Oncology. 32. S626–S627. 14 indexed citations

Iravani, Amir, Medhat Osman, Alison M. Weppler, et al.. (2020). FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment. European Journal of Nuclear Medicine and Molecular Imaging. 47(12). 2776–2786. 49 indexed citations

10.

Iravani, Amir, Arian Lasocki, Roslyn Wallace, et al.. (2020). SUN-127 Diagnostic Challenges Associated with the Rising Incidence of Endocrine Toxicity in the Era of Combination Immunotherapy. Journal of the Endocrine Society. 4(Supplement_1). 1 indexed citations

11.

Hepner, Adriana, Judith M. Versluis, Camille L. Gérard, et al.. (2020). The nature and management of acquired resistance to PD1-based therapy in melanoma.. Journal of Clinical Oncology. 38(15_suppl). 10014–10014. 3 indexed citations

12.

Trigos, Anna, Anupama Pasam, Patricia Banks, et al.. (2020). The tumor immune microenvironment of germline BRCA1/2 and sporadic prostate cancer.. Journal of Clinical Oncology. 38(6_suppl). 152–152. 1 indexed citations

13.

Iravani, Amir, Arian Lasocki, Roslyn Wallace, et al.. (2020). FDG PET in the evaluation of immune-related hypophysitis and thyroiditis following combination ipilimumab and nivolumab in advanced melanoma. 61. 482–482. 2 indexed citations

14.

Iravani, Amir, Arian Lasocki, Roslyn Wallace, et al.. (2020). OR32-06 Opportunistic Assessment of Pituitary Gland with Routine MRI and PET/CT Can Guide in Earlier and Increased Identification of Hypophysitis in Patients Treated with Combination Checkpoint Inhibitors. Journal of the Endocrine Society. 4(Supplement_1). 1 indexed citations

15.

Powell, Arfon, Roslyn Wallace, Ruth F. McKee, et al.. (2012). The relationship between tumour site, clinicopathological characteristics and cancer‐specific survival in patients undergoing surgery for colorectal cancer. Colorectal Disease. 14(12). 1493–1499. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact